Addressing Treatment Gaps in Gout
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Addressing Treatment Gaps in Gout” inside PodZeus.
This episode of The BioReport explores the persistent treatment gaps in gout, a common but often misunderstood form of inflammatory arthritis. Host Daniel Levine interviews James McKay, CEO of Crystallis Therapeutics, about the biology of gout, the limitations of current therapies like allopurinol and Crystexa, and the company’s next-generation URAT1 inhibitor, detenurad. McKay explains that gout is primarily caused by the kidneys’ inability to excrete uric acid in 85% of cases, leading to painful flares and long-term tissue damage, including cardiovascular and kidney risks. Despite the prevalence of asymptomatic hyperuricemia in 50 million Americans, patients often go undiagnosed and stigmatized. Crystallis is developing detenurad, a highly potent and safe URAT1 inhibitor already approved in Japan and China, with over 2.2 million patients treated post-marketing. The company’s Phase III trials are focused on patients failing standard care, measuring both uric acid reduction and patient-centered outcomes like flare frequency and tophi resolution. Regulatory strategy leverages strong Asian clinical data to support a streamlined development path, with a potential U.S. filing in 2028 and approval by late 2029. The company raised a record $205 million Series A, reflecting investor confidence in the de-risked asset and experienced team. Crystallis plans to commercialize independently with a newly hired CEO from Horizon Pharmaceuticals, and is exploring pipeline expansion into related areas like chronic kidney disease.
Gout is primarily caused by renal under-excretion of uric acid in 85% of patients, not diet, and leads to silent systemic inflammation even before flares occur.
Current standard therapies like allopurinol fail to achieve target uric acid levels in two-thirds of patients, creating a major unmet need in the second-line treatment space.
Crystallis Therapeutics’ detenurad is a next-generation URAT1 inhibitor with a thousand-fold higher potency than previous drugs and no renal toxicity, backed by five years of real-world safety data from over 2.2 million patients in Japan.
The company’s Phase III trials are designed to measure both regulatory endpoints (uric acid <6 mg/dL) and patient-centered outcomes, including gout flares and tophi resolution.
Regulatory strategy leverages extensive Asian clinical data, enabling a smaller, more efficient trial program and potential approval by late 2029.
…and 3 more takeaways available in PodZeus
The Hidden Burden of Gout
“Gout is not an autoimmune disease, but it's characterized by flares and periods of remission. What causes gout to flare? Is it understood? Yeah, it is.”
The Biology and Impact of Gout
Detailed explanation of gout’s pathophysiology: uric acid overproduction or under-excretion, crystal deposition in joints, and the resulting inflammatory flares. Emphasis on the systemic damage beyond joints, including cardiovascular and kidney risks.
Failures of Current Gout Therapies
“About two-thirds of people who are treated with allopurinol don't actually achieve uric acid target level.”
The Role of URAT1 and Crystallis’ Approach
“The drug is used quite broadly in Japan. The uptake over a five-year period has been impressive.”
Clinical Development and Regulatory Strategy
Details on Crystallis’ Phase III trials: Ruby (flares) and Topaz (tophi resolution), both focused on patients failing allopurinol. Use of patient-reported outcomes and regulatory leverage of Asian data.
“Crystallis Therapeutics’ detenurad is a next-generation URAT1 inhibitor with a thousand-fold higher potency than previous drugs and no renal toxicity.”
“Over 2.2 million patients have received the drug in a post-marketing setting in Japan, and there's been no change to the prescribing information over a five-year period.”
“Uric acid crystals can be thought of like matches which can sit quietly or can be ignited.”
Host
Guest
James McKay
person
Crystallis Therapeutics
organization
Detenurad
product
Japan
place
Allopurinol
product
URAT1
other
FDA
other
China
place
Zorampic
product
Horizon Pharmaceuticals
organization
Targeting Psychosis in Alzheimer’s Disease
The Bio Report • 22m • 4/1/2026
Intercepting Cancer When DNA Surveillance Fails
The Bio Report • 39m • 4/8/2026
Tuning, Rather than Blocking, Immunity in IBD
The Bio Report • 35m • 4/15/2026
Slowing Disability in MS
The Bio Report • 29m • 4/22/2026
An Off-the-Shelf Cell Therapy to Calm Cytokine Storms
The Bio Report • 28m • 4/29/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Addressing Treatment Gaps in Gout” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime